Innate Pharma Reports Full-Year 2025 Financial Results and Business Update

Innate Pharma reported its 2025 financial results and business update. Lacutamab's confirmatory Phase 3 trial in cutaneous T-cell lymphoma is planned for H2 2026, subject to non-dilutive financing options. IPH4502 (Nectin-4 ADC) shows preliminary anti-tumor activity and a favorable safety profile. The Monalizumab PACIFIC-9 Phase 3 trial continues to advance toward a planned H2 2026 data readout. IPH5201 (anti-CD39 antibody) interim results have been selected for an oral presentation at the AACR Annual Meeting 2026. The company has a cash position of €44.8 million as of December 31, 2025, with an anticipated cash runway until the end of Q3 2026.